Gavin Cull

3.0k total citations
67 papers, 1.2k citations indexed

About

Gavin Cull is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Gavin Cull has authored 67 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Genetics, 34 papers in Pathology and Forensic Medicine and 21 papers in Hematology. Recurrent topics in Gavin Cull's work include Chronic Lymphocytic Leukemia Research (34 papers), Lymphoma Diagnosis and Treatment (33 papers) and CNS Lymphoma Diagnosis and Treatment (11 papers). Gavin Cull is often cited by papers focused on Chronic Lymphocytic Leukemia Research (34 papers), Lymphoma Diagnosis and Treatment (33 papers) and CNS Lymphoma Diagnosis and Treatment (11 papers). Gavin Cull collaborates with scholars based in Australia, New Zealand and United States. Gavin Cull's co-authors include Paula Marlton, Stephen Opat, Constantine S. Tam, David Simpson, Devinder Gill, Judith Trotman, Paul Cannell, Ralph Cobcroft, Javier Muñoz and Jenny Byrne and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.

In The Last Decade

Gavin Cull

63 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gavin Cull Australia	17	662	601	367	332	230	67	1.2k
Wataru Munakata Japan	18	649 1.0×	347 0.6×	459 1.3×	161 0.5×	173 0.8×	103	1.1k
Anne Lennard United Kingdom	20	831 1.3×	562 0.9×	561 1.5×	414 1.2×	168 0.7×	51	1.6k
Deepa Jagadeesh United States	17	660 1.0×	273 0.5×	652 1.8×	169 0.5×	172 0.7×	123	1.1k
J. M. Vose United States	15	801 1.2×	289 0.5×	596 1.6×	243 0.7×	198 0.9×	34	1.2k
Nicole Straetmans Belgium	17	546 0.8×	333 0.6×	572 1.6×	272 0.8×	97 0.4×	44	1.1k
Deborah Marcellus United States	19	495 0.7×	240 0.4×	555 1.5×	491 1.5×	153 0.7×	30	1.2k
Livio Gargantini Italy	19	563 0.9×	311 0.5×	396 1.1×	286 0.9×	193 0.8×	31	1.1k
SJ Horning United States	18	1.0k 1.5×	418 0.7×	884 2.4×	349 1.1×	173 0.8×	39	1.7k
Yves Réguerre France	18	326 0.5×	261 0.4×	522 1.4×	367 1.1×	118 0.5×	64	1.3k
Ronit Gurion Israel	17	344 0.5×	216 0.4×	381 1.0×	237 0.7×	110 0.5×	83	830

Countries citing papers authored by Gavin Cull

Since Specialization

Citations

This map shows the geographic impact of Gavin Cull's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gavin Cull with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gavin Cull more than expected).

Fields of papers citing papers by Gavin Cull

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gavin Cull. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gavin Cull. The network helps show where Gavin Cull may publish in the future.

Co-authorship network of co-authors of Gavin Cull

This figure shows the co-authorship network connecting the top 25 collaborators of Gavin Cull. A scholar is included among the top collaborators of Gavin Cull based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gavin Cull. Gavin Cull is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bromberg, Jacoline E. C., Samar Issa, Bronno van der Holt, et al.. (2023). Survival, neurocognitive function, and health-related quality of life outcomes after rituximab—methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study. Neuro-Oncology. 26(4). 724–734. 5 indexed citations

Tam, Constantine S., Mazyar Shadman, Jeff P. Sharman, et al.. (2023). PB1926: EFFICACY AND SAFETY OF ONCE DAILY (QD) VS TWICE DAILY (BID) ZANUBRUTINIB FOR PATIENTS WITH VARIOUS B-CELL MALIGNANCIES: A COMPARATIVE SUMMARY OF CLINICAL DATA AND EXPOSURE-RESPONSE ANALYSES. HemaSphere. 7(S3). e70124b5–e70124b5. 1 indexed citations

Meulen, Matthijs van der, Linda Dirven, Esther J. J. Habets, et al.. (2021). Neurocognitive functioning and radiologic changes in primary CNS lymphoma patients: results from the HOVON 105/ALLG NHL 24 randomized controlled trial. Neuro-Oncology. 23(8). 1315–1326. 9 indexed citations

Tam, Constantine S., Stephen Opat, David Simpson, et al.. (2021). Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Blood Advances. 5(12). 2577–2585. 63 indexed citations

Trotman, Judith, Stephen Opat, David Gottlieb, et al.. (2020). Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. Blood. 136(18). 2027–2037. 73 indexed citations

Meulen, Matthijs van der, Katerina Bakunina, Marcel Nijland, et al.. (2020). Health-related quality of life after chemotherapy with or without rituximab in primary central nervous system lymphoma patients: results from a randomised phase III study. Annals of Oncology. 31(8). 1046–1055. 4 indexed citations

Wood, Benjamin A., et al.. (2020). Hydroa Vacciniforme-Like Lymphoproliferative Disorder in an Adult Patient With Chronic Lymphocytic Leukemia. Journal of Medical Cases. 11(11). 366–369.

Trotman, Judith, Stephen Opat, Paula Marlton, et al.. (2019). PF481 UPDATED SAFETY AND EFFICACY DATA IN A PHASE 1/2 TRIAL OF PATIENTS WITH WALDENSTRÖM MACROGLOBULINAEMIA (WM) TREATED WITH THE BRUTON TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB (BGB‐3111). HemaSphere. 3(S1). 192–193. 3 indexed citations

Steiner, Raphaël, Chelsea C. Pinnix, Bouthaina S. Dabaja, et al.. (2019). An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement. Cancer Medicine. 9(2). 663–670. 16 indexed citations

10.

Dimopoulos, Meletios Α., Stephen Opat, Gavin Cull, et al.. (2019). PF487 MAJOR RESPONSES IN MYD88 WILDTYPE (MYD88WT) WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH BRUTON TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB (BGB‐3111). HemaSphere. 3(S1). 196–196. 7 indexed citations

11.

Cull, Gavin, Stephen Opat, Judith Trotman, et al.. (2017). Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Combination with the PD-1 Inhibitor BGB-A317 in Patients with B-Cell Lymphoid Malignancies. Blood. 130. 4057–4057. 2 indexed citations

12.

Ghassemifar, Reza, et al.. (2012). Differential expression of the Bcl-2 and Bax isoforms in CD19 positive B-lymphocytes isolated from patients diagnosed with chronic lymphocytic leukaemia. Pathology. 44(7). 632–637. 5 indexed citations

13.

Gill, Saar, Steven Lane, Julie Crawford, et al.. (2008). Prolonged haematological toxicity from the hyper-CVAD regimen: manifestations, frequency, and natural history in a cohort of 125 consecutive patients. Annals of Hematology. 87(9). 727–734. 14 indexed citations

14.

Isbister, Geoffrey K., Mark Little, Gavin Cull, et al.. (2007). Thrombotic microangiopathy from Australian brown snake (Pseudonaja) envenoming. Internal Medicine Journal. 37(8). 523–528. 51 indexed citations

15.

Lane, Steven, Julie Crawford, Melita Kenealy, et al.. (2006). Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy. Leukemia & lymphoma. 47(9). 1813–1817. 18 indexed citations

16.

Henley, David, Jane Kaye, John P. Walsh, & Gavin Cull. (2005). Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma. Internal Medicine Journal. 35(12). 726–728. 16 indexed citations

17.

Haynes, A. P., Jenny Byrne, Gavin Cull, et al.. (2001). Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM–CAMPATH (± fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion. Cytotherapy. 3(3). 203–210. 19 indexed citations

18.

Russell, NH, Gavin Cull, Jenny Byrne, et al.. (1999). Evaluation of non-myeloablative conditioning combining beam with in vivo pre-transplant Campath-IG for allogeneic transplantation in patients with lymphoma.. Blood. 94. 5 indexed citations

19.

Cull, Gavin, et al.. (1997). Collection and Recruitment of CD34+ Cells During Large-Volume Leukapheresis. Journal of Hematotherapy. 6(4). 309–314. 35 indexed citations

20.

Cull, Gavin, John W. Eikelboom, & Paul Cannell. (1997). Exacerbation of coagulopathy with concurrent bone marrow necrosis, hepatic and renal dysfunction secondary to all-trans retinoic acid therapy for acute promyelocytic leukemia. Hematological Oncology. 15(1). 13–17. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact